Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
Date:10/28/2008

Fourth Innovation Award for Abbott in Six Years Recognizes Breakthrough

Treatment for the Most Common Form of Heart Disease

ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott today announced it has received a 2008 Chicago Innovation Award for its XIENCE V(TM) Everolimus Eluting Coronary Stent System. Based on the product's innovative design and strong clinical data, the next-generation drug eluting stent represents a significant advance in the treatment of coronary artery disease.

Abbott's XIENCE V stent was approved by the United States Food and Drug Administration (FDA) and launched in July 2008, providing a new treatment option for the nearly 13 million Americans with coronary artery disease, the leading cause of death for both men and women in the United States. Stents are designed to prop open an artery that has become clogged by plaque build-up and restore blood flow to the heart. A drug eluting stent releases a medication (everolimus, in the case of XIENCE V) in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is the only drug eluting stent to demonstrate superiority over the previous market-leading drug eluting stent in two randomized, pivotal clinical trials -- and XIENCE V has become the market-leading drug eluting stent in just three months since launch.

This is the fourth Chicago Innovation Award that Abbott has received in six years. Most recently, the company's m2000(TM) molecular diagnostic instrument in combination with the RealTime HIV-1 viral load test received the honor in 2007. In 2005, the company's PathVysion(TM) breast cancer test received the honor, and in 2003, HUMIRA(TM), the first human monoclonal antibody drug for rheumatoid arthritis, won the award.

"At Abbott, we are proud to be in the business of developing innovative treatments that improve and save lives," said Miles D. White, chairman and chief executive officer, Abbott. "Receivi
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
2. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
3. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
4. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
5. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
6. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
10. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
11. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 BerGenBio AS ("BerGenBio" or ... an abstract on the latest data on BGB324, the ... receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal ... in conjunction with the 2015 American Society of Clinical ... , May 29 - June 2, 2015. ...
(Date:5/29/2015)... 29, 2015 Market Publishers Ltd ... signed a partnership agreement for quality market research ... distribute and sell research reports worked out by ... Department, commented upon the agreement: “Chem-Report is a ... petroleum and chemical markets on global and country ...
(Date:5/29/2015)... Texas , May 29, 2015  Caris ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the clinical utility of Caris ... tumor profiling service, in helping to identify targeted ... tumors. In each of the studies, results of ...
(Date:5/29/2015)... Seoul Semiconductor (CEO: Chung-hoon Lee, http://www.seoulsemicon.com ... 28th announced that it will increase the global ... efficient and high reliable LED product line-up for ... has developed efficient and reliable LED packages for ... for headlamps to global auto makers. Seoul Semiconductor’s ...
Breaking Biology Technology:BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2
...  Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology ... results for the first quarter ended March 31, 2012 ... will host a conference call at 5:00 p.m. Eastern ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ) Those wishing to ...
... announced today the launch and immediate availability of the GS GType ... variation detection in four key human genes using the company,s ... sequence-based assays offer a new solution for cancer researchers investigating the ... RUNX1 genes, which are known to be associated with ...
... research team this week will present findings that they ... and breast cancer. "Cells have different ... chemical name for alcohol, that represent a potential risk ... pharmacology and toxicology at the Universidad Autonoma del Estado ...
Cached Biology Technology:Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide 2Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide 3Researchers Find Potential Link Between Drinking Alcohol And Breast Cancer 2Researchers Find Potential Link Between Drinking Alcohol And Breast Cancer 3
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... released today in the EarlyView of Ecology Letters ... shift in biomes caused by a warming climate. The ... Center and three other institutions based in Alaska and ... tree-ring data set. Patterns observed support current hypotheses regarding ...
... It,s a discordant note in the symphony of ... Stem cells hold enormous promise in regenerative medicine, thanks ... They have made it possible to markedly improve the ... cases of dystrophy, skin grafts for treating burn victims, ...
... breakthrough, a new blood pressure measurement device is set to ... new approach, invented by scientists at the University of Leicester ... treat their patients more effectively because it gives a more ... by measuring the pressure close to the heart the ...
Cached Biology News:New study illustrates shifting biomes in Alaska 2Reprogrammed stem cells hit a roadblock 2Groundbreaking technology will revolutionize blood pressure measurement 2Groundbreaking technology will revolutionize blood pressure measurement 3Groundbreaking technology will revolutionize blood pressure measurement 4
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
... GenBank Accession Number : ... (C-QSQENQDTRPKVKAKK), corresponding to amino acids ... Formulation: antiserum in 0.05% sodium ... Assurance: routinely evaluated by immunoblot ...
Request Info...
...
Biology Products: